Evidence map›Paper›PMID 42516903›Full record

ArticleERJ open research2026

Moderate hypoxaemia and cognitive impairment in individuals with cigarette smoke exposure.

T Mitchell Mazza, Chloe Hill, Dan Pergel, Devin J Burke, Katherine A Pratte, Russell P Bowler, Craig P Hersh, Stephen J Glatt, Jonathan L Hess, Karin F Hoth and 1 more

Abstract read
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

T Mitchell MazzaDivision of Pulmonary, Critical Care, and Sleep Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA.ORCID https://orcid.org/0009-0005-0122-2208
Chloe HillDivision of Pulmonary, Critical Care, and Sleep Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA.
Dan PergelDivision of Pulmonary, Critical Care, and Sleep Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA.
Devin J BurkeDepartment of Neurology, SUNY Upstate Medical University, Syracuse, NY, USA.ORCID https://orcid.org/0000-0002-8872-6433
Katherine A PratteDepartment of Biostatistics, National Jewish Medical and Research Center, Denver, CO, USA.
Russell P BowlerDepartment of Genomic Sciences and Systems Biology, Cleveland Clinic Research, Cleveland, OH, USA.ORCID https://orcid.org/0000-0003-4651-363X
Craig P HershChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Stephen J GlattDepartment of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.
Jonathan L HessDepartment of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.
Karin F HothDepartment of Psychiatry, University of Iowa, Iowa City, IA, USA.ORCID https://orcid.org/0000-0002-4261-5308
Auyon J GhoshDivision of Pulmonary, Critical Care, and Sleep Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA.ORCID https://orcid.org/0000-0003-0334-4039

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
GENETIC EPIDEMIOLOGY OF COPD (COPD GENE) TASK A: STUDY VISIT 4, COLLECTION OF COPDGENE STUDY DATA ANDBIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY75N92023D00011 · NHLBI · NATIONAL JEWISH HEALTH · PI NEWMAN, LEE S · 2023 to 2025
$29.6M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
Biomarker of Lung Disease in African AmericansR01HL137995 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL, KECHRIS-MAYS, KATHERINA · 2018 to 2021
$3.4M
Integrating Genetic, Neuroimaging, Transcriptomic, and Clinical Risk Factors as Multivariate Predictors of Cognitive Deterioration in Alzheimer's Disease.R01NS128535 · NINDS · UPSTATE MEDICAL UNIVERSITY · PI HESS, JONATHAN · 2022 to 2024
$1.2M
Genetic and Transcriptomic Resilience in Chronic Obstructive Pulmonary DiseaseK08HL168205 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI Auyon Ghosh · 2024 to 2026
$608k
Patient oriented research and mentoring in COPD biomarker studiesK24HL173667 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAIG P HERSH · 2025 to 2026
$264k
NHLBI NIH HHS 75N92023D00011NHLBI NIH HHS K08 HL168205NHLBI NIH HHS K24 HL173667NHLBI NIH HHS R01 HL137995NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NINDS NIH HHS R01 NS128535
6 · The paper itself

Abstract

Background: Cognitive impairment (CI) is among the extrapulmonary comorbidities that are increasingly recognised in individuals with COPD and a history of cigarette smoke exposure. While severe hypoxaemia is a well-established risk factor for CI, the role of moderate hypoxaemia (peripheral oxygen saturation ( Methods: We evaluated the association between moderate hypoxaemia, assessed by pulse oximetry, and CI in participants from the Genetic epidemiology of COPD (COPDGene) study who completed the Phase 3 (10-year follow-up) visit. We performed mediation analysis of moderate hypoxaemia on the association between COPD and CI. We tested for differences in proteomic biomarkers of cerebral hypoxia and performed differential gene expression and pathway enrichment analyses to compare individuals with moderate hypoxaemia with those with CI. Findings: We found that moderate hypoxaemia at the 5-year follow-up visit, but not at the baseline visit, is associated with CI as assessed at the 10-year follow-up visit (OR 1.49, 95% confidence interval 1.10-1.99). In addition, moderate hypoxaemia significantly mediates the association between COPD and CI (average causal-mediated effect, 27.3%; p<0.001). Out of 38 proteins previously associated with cerebral hypoxia, 13 were significantly associated with moderate hypoxaemia. Interpretation: Our study establishes moderate hypoxaemia as an important risk factor for CI in individuals with a history of cigarette smoke exposure and as a mediator of the risk of CI in individuals with COPD. We also identify multi-omic biomarkers that better characterise the biological pathways underlying the association between moderate hypoxaemia and CI. Future studies are needed to identify individuals with moderate hypoxaemia who are at the highest risk of CI.

Identifiers

PMID42516903
PMCPMC13402997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.